STOK Stock — Stoke Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (“ASOs”) to selectively restore protein levels.

Source: 10-K FY2025 via SEC EDGAR

Share price

$26.54

Market cap

$1,735.9M

Cash

$358.8M

Enterprise value

$1,377.1M

Balance sheet

Cash	$358.8M
Debt	$0.0M
Net cash	$358.8M
Enterprise value	$1,377.1M
Basic shares	65.4M shares
Fully diluted shares	69.1M shares
Fully diluted market cap	$1,834.2M
Cash per share	$5.49
Quarterly burn	$56.6M
Cash runway	6.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

65.4M

Pre-funded warrants

—

Options

—

RSUs

—

Warrants

3.7M

Converts

0.0M

Conv preferred

—

ESPP reserve

—

FDSO

69.1M

Cap table as of 2026-11-03.

Price history

Loading STOK daily closes…

Loading price history…

Next catalyst

zorevunersen · Apr 12 - May 24 in 5 mo · Phase 3 · Dravet Syndrome

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24 in 5 mo	zorevunersen	Phase 3	Dravet Syndrome	Q3 2027 Est. Aug 15, 2027 · quarter midpoint
May 12 - Jun 23 in 31 mo	zorevunersen (STK-001)	Phase 2	Dravet Syndrome	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

zorevunersen

Phase 3 · Active Modality: ASO (TANGO protein-upregulation)

Aliases STK-001

Target SCN1A (Nav1.1)

Partnerships Biogen: exclusive license to develop and commercialize outside the US, Canada and Mexico; joint development with Company leading globally (70/30 cost share)

Indications

Dravet syndrome (Phase 3)

Catalysts

— Q1 2027
— Q3 2027 / H2 2027
— early 2028

Status note Lead candidate. Global pivotal Phase 3 EMPEROR study enrolled 162 patients (completed June 2026); Phase 1/2a and OLE studies completed. Breakthrough Therapy Designation (Dec 2024).

STK-002

Phase 1 · Active Modality: ASO (TANGO protein-upregulation)

Target OPA1

Indications

Autosomal dominant optic atrophy (ADOA) (Phase 1)

Catalysts

— H1 2027

Status note Phase 1 OSPREY dose-escalation study ongoing; first patient dosed February 2026; eight sites active across UK, Germany, Austria, Italy and Denmark.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	zorevunersen
Lead indication	Dravet Syndrome
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06872125	Phase 3	Recruiting	Sponsor	STOK	—	Dravet Syndrome	Q3 2027 Est. Aug 15, 2027 · quarter midpoint
NCT04740476	Phase 2	Active, not recruiting	Sponsor	STOK	—	Dravet Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Stoke Therapeutics, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	5,623,525	no change	1.57%	2026-08-14
Baker Bros. Advisors	3,336,697	no change	0.55%	2026-08-14
BVF Partners	2,547,557	no change	2.13%	2026-08-14
Deerfield Management	1,823,500	no change	0.62%	2026-08-14
EcoR1 Capital	735,000	+635,000	1.19%	2026-08-14
Tang Capital Partners	300,000	-200,000	0.45%	2026-08-14
DAFNA Capital	130,875	no change	0.82%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

STOK — Stoke Therapeutics Inc. ☆